Further analyses indicated that TTB to prevent 1 clinical event for 500, 200, 100, and 50 patients with HF receiving SGLT2 inhibitors was 0.19, 0.66, 1.74 and 4.96 months, respectively, suggesting the early benefit of SGLT2 inhibitors among patients with HF. Here, SLC5A2 is linked to hydrops fetalis.